IGF-1 LR3 vs Tesamorelin: Literature and Handling Compared
The practical distance between IGF-1 LR3 and Tesamorelin shows up first in how much published methodology exists for each.
Side-by-side research profile
| Parameter | IGF-1 LR3 | Tesamorelin |
|---|---|---|
| PubMed indexed records | 11 | 121 |
| Registered studies (ClinicalTrials.gov) | 0 | 24 |
| Literature depth | Emerging | Moderate |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Compound profiles
IGF-1 LR3 in the indexed record
Indexed output for IGF-1 LR3 stands at 11 records, a limited literature with no registered studies currently listed on ClinicalTrials.gov.
Publications carrying this compound include Am J Physiol Endocrinol Metab, Appl Microbiol Biotechnol, FASEB J, spanning 2020–2025.
- Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris — Appl Microbiol Biotechnol, 2023. PMID: 37261455
- IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep — Am J Physiol Endocrinol Metab, 2025. PMID: 39679943
- Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets — J Dev Orig Health Dis, 2023. PMID: 37114757
- Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration — Int J Biol Macromol, 2025. PMID: 41015370
Tesamorelin in the indexed record
Indexed output for Tesamorelin stands at 121 records, a moderate literature, alongside 24 registered studies on ClinicalTrials.gov.
Publications carrying this compound include Ann Pharmacother, BETA, Curr Opin Investig Drugs, spanning 2006–2012.
- Tesamorelin — , 2012. PMID: 31644039
- Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy — Ann Pharmacother, 2012. PMID: 22298602
- Tesamorelin, a human growth hormone releasing factor analogue — Expert Opin Investig Drugs, 2009. PMID: 19243281
- Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy — Drugs, 2011. PMID: 21668043
How the literature differs
The indexed record is not symmetrical between these two compounds. Tesamorelin carries 110 more indexed records than IGF-1 LR3, which means published methodology, characterisation data and replication attempts are more readily located for Tesamorelin. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (0 vs 24) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Classification and why it matters
IGF-1 LR3 and Tesamorelin sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for IGF-1 LR3 describes conditions validated for IGF-1 LR3: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Tesamorelin without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Documentation standards
Identity and purity are separate claims requiring separate methods. A purity percentage quoted without the analytical method behind it, or a certificate with no lot reference, is a documentation gap rather than verification.
Selecting between them for a study design
IGF-1 LR3 and Tesamorelin are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (Tesamorelin) generally offers more methodological precedent.
Storage and stability
Lyophilised peptide is the stable form. Held sealed at -20°C and shielded from light, it tolerates long storage; once reconstituted that tolerance drops sharply and the working solution is treated as short-lived.
Each freeze-thaw cycle costs integrity, which is why reconstituted material is normally split into single-use aliquots.
Frequently asked questions
Which of IGF-1 LR3 or Tesamorelin has more published research?
Tesamorelin, with 121 indexed PubMed records against 11.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Are IGF-1 LR3 and Tesamorelin the same compound?
No. They are structurally distinct research compounds with separate literature records — 11 indexed records for IGF-1 LR3 and 121 for Tesamorelin.
Related references
- IGF-1 LR3 — product and lot documentation
- Tesamorelin — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.